UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20

Benzinga · 4d ago
UBS analyst Michael Goldsmith maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and lowers the price target from $21 to $20.